- Bayer (OTCPK:BAYRY) is considering expanding its agreement with CureVac (NASDAQ:CVAC) to include the production of German biopharmaceutical company’s coronavirus vaccine candidate CVnCoV, reports Welt am Sonntag.
- In an interview with the German newspaper, the CEO of Bayer, Werner Baumann, has said that the expansion of the cooperation to include vaccine production will be "intensively examined."
- In early January, Bayer joined CureVac in a collaboration and services agreement whereby the former takes responsibility for further development, supply, and key territory operations of CureVac’s mRNA-based vaccine candidate against COVID-19.
- CEO’s remarks come after Pfizer (NYSE:PFE) confirmed on Friday a temporary cutback in the COVID-19 vaccine supply in Europe until it upgrades the production capacity in the region. In December, the mRNA-based vaccine of the company co-developed with BioNTech (NASDAQ:BNTX) received conditional approval in Europe.